ASX Share rice
Sat 08 Aug 2020 - 07:11:pm (Sydney)

PTX Share Price

PRESCIENT THERAPEUTICS LIMITEDPTXPharmaceuticals, Biotechnology & Life Sciences

PTX Company Information


Prescient Therapeutics Limited





GIC Industry:


GIC Sub Industry:



100 Albert Road South Melbourne VIC Australia 3205


61 3 9692 7222

MD, CEO & Director:

Mr. Yatomi-Clarke Steven Lee

CFO & Company Sec.:

Ms. Melanie Jaye Leydin C.A., B.Bus, CA

Chief Scientific Officer:

Prof. Said M. Sebti Ph.D., M.D.

Chief Medical Officer:

Dr. Terrence G. Chew

Head of Bus. Devel.:

Dr. James D. Winkler

Company Overview:

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company's lead drug candidate is PTX-200, which is in Phase II clinical trial for negative breast cancer, as well as Phase IB clinical trial in relapsed and refractory ovarian cancer and acute leukemia; and PTX-100, a treatment that has completed Phase I clinical trial for solid tumors. Prescient Therapeutics Limited has a collaboration agreement with Carina Biotech to develop cellular therapies; and a research agreement with the Peter Doherty Institute for Infection and Immunology for SARS-CoV-2 antiviral drugs program. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited is based in South Melbourne, Australia.

PTX Share Price Information

Shares Issued:


Market Capitalisation:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Profit Margin:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


PTX CashFlow Statement

CashFlow Date:


Change To Liabilities:


Net Borrowings:


Net Income:


Total Cash From Operating Activities:




Change To Account Receivables:


Sale Purchase Of Stock:


Capital Expenditures:


PTX Income Statement

Income Date:


Income Before Tax:


Net Income:


Gross Profit:


Operating Income:


Interest Expense:


Total Revenue:


Total Operating Expenses:


PTX Balance Sheet

Balance Sheet Date:


Intangible Assets:


Total Liabilities:


Total Stockholder Equity:


Other Current Liabilities:


Total Assets:


Common Stock:


Other Current Assets:


Retained Earnings:


Other Liabilities:




Total Current Liabilities:


Property - Plant & Equipment:


Net Tangible Assets:


Total Current Assets:


Net Receivables:


Short-Term Investments:


Accounts Payable:


Non Currrent Assets (Other):


Short-Term Investments:


Non Current Liabilities Total:


PTX Share Price History

PTX News

11 May, 2020
In 2016, Yatomi-Clarke Lee was appointed CEO of Prescient Therapeutics Limited (ASX:PTX). First, this article will...
12 Mar, 2020
Generally speaking long term investing is the way to go. But that doesn't mean long term investors can avoid big...
27 Jan, 2020
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
11 Oct, 2019
Every investor in Prescient Therapeutics Limited (ASX:PTX) should be aware of the most powerful shareholder groups...
23 Aug, 2019
In 2016 Yatomi-Clarke Lee was appointed CEO of Prescient Therapeutics Limited (ASX:PTX). This analysis aims first to...